building bridges to better vision annual report 2008 · at left, top to bottom: emily chew, md,...

2008annual report

B U I L D I N G B R I D G E S T O B E T T E R V I S I O N

2 YEAR- IN -REV IEW

6 PAT IENT CARE

8 EDUCAT ION

12 RESEARCH

16 DONORS SUPPORT RESEARCH MISS ION

18 CL IN ICAL & RESEARCH FACULTY & STAFF

20 CL IN ICAL TR IALS

24 AWARDS, LECTURES & PUBL ICAT IONS

28 DONOR HONOR ROLL

29 REVENUE SUMMARY

29 VOLUNTEER & AFF IL IATE FACULTY MEMBERS

30 GRANTS

COVER PHOTOS:

From left to right: Stephen Sauer, MD. See story page 8. Gillian McLellan, BVMS, PhD. See story page 12. Gregg Heatley, MD and Robert Nickells, PhD. See story page 14.

At left, top to bottom: Emily Chew, MD, from the National Eye Institute. See story page 2. Mark Lucarelli, MD, see story page 2. Burton Kushner, MD, and Beth Kunz, see story page 6.

table of contents

Let me tell you a story.

It’s the story of a man who has been instrumental in supporting not only the UW Department of Ophthalmology and Visual Sciences, but the entire University of Wisconsin System. It’s the story of a son who turned down a job on Wall Street to return to Madison to practice law with his father; the story of a father who has watched two of his children battle chronic health problems; the story of a humble man who has used his varied connections to bridge a gap between those who need funding to conduct research and the foundations that are able to support research.

Our Department is proud to call this man, David Walsh, a friend. He’s the kind of friend who will ask a great deal and offer more in return. He’s a straight-shooting friend – honest in his assessment of what makes us good, and what we need to improve. Read his story on page 16.

Just as David Walsh helps us see what’s possible, our researchers, both basic scientists and clinical

researchers, are continuously working together to develop treatments for blinding diseases and disorders. Research takes us down many paths, but the beauty of a Department like ours is that the high level of collaboration among researchers of many disciplines means better science all around. Read about one collaborative group, the glaucoma researchers, on page 12.

We have a new friend in Beth Kunz, a little girl who saw many physicians before she came to Burton Kushner, MD, chief of the pediatric ophthalmology service in our Department. He was able to correctly diagnose what was causing her vision problems and connect her with other physicians who performed an arduous procedure to fix the problem and avoid more damage in the future. Her story is told on page 6.

Physicians who work at an academic medical center such as ours are committed not only to research, but to training ophthalmologists of the future. Our residency program was recently reaccredited for four

years. We take great pride in the quality of the residency experience we provide and the accomplishments of our graduates. Read about changes to the residency program beginning on page 8.

We are pleased to share news of our Department with all of you, our colleagues, collaborators and friends, near and far. If you have any questions or comments about this annual report, please contact Sarah Fuelleman ([email protected]).

Paul L. Kaufman, MDPeter A. Duehr Professor and Department ChairUW Department of Ophthalmology and Visual SciencesUniversity of Wisconsin School of Medicine and Public Health

from the chair

Paul L. Kaufman, MD

2008 ANNUAL REPORT 1

UW DEPARTMENT OF OPHTHALMOLOGY AND VISUAL SCIENCES

year in review

2

ACCOMPL ISHMENTS IN PAT IENT CARE

Cl i n i C Mo v e s

In fall 2008, UW Health Rockford Eye moved to a new location on Rote Road. The new building offers more room for staff and patients and is easier to get to as well.

Clinic visits are now more efficient, with one person performing a test in one exam room while a physician is conducting an exam in another. In the past, the crowded conditions were less efficient.

Specialists at the Rockford location include pediatric ophthalmologists, retina specialists and oculoplastic specialists.

sa t u r d a y Cl i n i C se r v e s Po P u l a t i o n i n ne e d

About 150 local residents receive free eye care each year through a monthly Saturday clinic at University Station in Madison. The clinics are staffed by medical residents and supervised by attending physicians in the Department of Ophthalmology and Visual Sciences.

The patients are referred to the Saturday clinic from Community Health Access, which also screens for financial need. These are patients who might otherwise not be able to get new glasses or have their eye disorders treated. The UW Health Optical Shops also help out with free glasses for these patients.

to P do C s

Gregg A. Heatley, MD, and John E. Temprano, MD, garnered “Top Docs 08” awards for Ophthalmology from Madison Magazine.

Medical receptionist Peggy Petitt, right, chats with Doris Guetschow, a patient at UW Health Rockford Eye. For Guetschow, the new location is more convenient and welcoming than the former office.

Gregg A. Heatley, MD John E. Temprano, MD


Suresh Chandra, MD, a retina specialist at the University of Wisconsin Department of Ophthalmology & Visual Sciences, treats a patient during a free Clinic at UW Health University Station. These clinics serve patients who cannot otherwise afford care.

ACCOMPL ISHMENTS IN EDUCAT ION

ex t r a o r d i n a r y oP h t h a l M o l o g y

Ophthalmologists and vision researchers attended the first-ever Extraordinary Ophthalmology Conference July 11 and 12 in Madison. This conference combined clinical and basic science research talks applicable to ophthalmology. The conference focused on advances in ophthalmology practice, global prevention of blindness, and research advances that will influence ophthalmic practice in the

future including nanotechnology, stem cell research and robotics.

About 160 people from the United States as well as from India, Canada, the United Kingdom and Turkey attended.

Approximately 600 people attended the Macular Degeneration Symposium October 14 at the Alliant Energy Center in Madison. The day-long event is sponsored by the UW Department of Ophthalmology and Visual Sciences and the Wisconsin Council of the Blind and Visually Impaired. It is designed for

people with macular degeneration and their caregivers to learn more about the disease. Planning for the next macular degeneration symposium is under way.

More than 40 residents from the UW Department of Ophthalmology and Visual Sciences as well as the UW School of Veterinary Medicine; University of Iowa, Department of Ophthalmology and Visual Sciences; the Medical College of Wisconsin, Department of Ophthalmology; and Northwestern University attended the Phacoemulsification Course in 2008.

Participants at the Macular Degeneration Symposium visit with a vendor displaying low-vision aids at the Alliant Energy Center.


year in review

4

continued

The course enables residents to learn and practice surgical technique without compromising patient safety. Phacoemulsification is the best surgery to treat cataracts but it is technically challenging. The annual course gives residents the opportunity to practice and to learn about complications and corrections. Andrew Thliveris, PhD, MD, an associate professor with the UW Department of Ophthalmology at Visual Sciences and chief of ophthalmology and the William S. Middleton Memorial Veterans Hospital in Madison, directs the course.

ACCOMPL ISHMENTS IN RESEARCH

A 25-year study of people with Type 1 diabetes in Wisconsin has some good news: People who controlled their blood-sugar levels over the long term were more likely to reverse certain abnormalities, caused by the disease, in the retina’s small blood vessels.

The study, led by Ronald Klein, MD, MPH, professor of ophthalmology and visual sciences at UW School of Medicine and Public Health, appeared in the November edition of Ophthalmology.

Dr. Klein and his colleagues have been monitoring the health of 996 southern Wisconsin people who were diagnosed with Type 1 (insulin-dependent) diabetes before the age of 30. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, funded by the National Eye Institute, began in 1979 and followed participants with Type 1 diabetes through 2007. The research participants had their glycosylated hemoglobin levels (a measure of average blood sugar levels over the previous three months) measured regularly and their eye health checked through photographs of the back of their eyes (the retina) taken with a special camera. Diabetic

retinopathy (signs of damage to the small retinal blood vessels) were detected by grading these photographs at periodic examinations over the 25 years of the study.

But then there’s the bad news: Serious eye disease is a very common side effect of diabetes. Based on the Wisconsin findings, 185,000 to 466,000 Americans with Type 1 diabetes may eventually develop proliferative diabetic retinopathy, a condition that can lead to severe visual impairment.

Poor blood-sugar control was strongly related to development of proliferative diabetic retinopathy. Other factors that increased the risk for developing proliferative diabetic retinopathy included being male; being overweight; having higher blood pressure; and having protein in the urine, a sign of diabetic kidney disease.

In about 18 percent of people, the diabetic retinopathy improved. This improvement was more likely in those with better control of their blood sugar.

There is some other good news in the study. “Interestingly, we saw less progression to proliferative diabetic retinopathy among people who had a similar duration of Type 1 diabetes but who were diagnosed more recently,’’ Dr. Klein said. “The biggest reason seems to be an improvement in the management of blood sugar and blood-pressure levels in people with diabetes.” :

David Dueker, MD, an ophthalmologist at the Medical College of Wisconsin, watches a resident perform part of a procedure. A large laboratory at the School of Veterinary Medicine holds all six of the wet lab stations for the phacoemulsification course. Each resident rotates through the stations (denoted by colored balloons), allowing each resident to practice every aspect of phaco surgery.

Ronald Klein, MD, MPH


Dr. Klein shows the portable camera used in an epidemiology study.

Ronald Klein, MD, MPH, uses a portable digital camera to take a photograph of a patient’s lens.

na t i o n a l i n s t i t u e s o f he a l t h fu n d i n g

The UW Department of Ophthalmology and Visual Sciences received $9,127,243 in 18 awards from the NIH in 2008. This was up from $8,056,228 in 2007.


patient care

6

inter-departmental team provides outstanding care

PEDIATR IC PAT IENT bENEF I TS FROM L INkS bETWEEN UW HEALTH SPECIAL ISTS

Beth Kunz, now 3-years-old, is a happy child who adores her doctor, Burton Kushner, MD. But there was a time when seeing Dr. Kushner, a pediatric ophthalmologist at the UW Department of Ophthalmology and Visual Sciences, was not so much fun.

Beth’s mom, Amy Kunz, recalls the struggle the family had finding out what was going on with Beth’s vision. “We saw her regular pediatrician because Beth had a head tilt. We saw physical therapists, orthopedic physicians and had X-rays and they couldn’t find anything wrong.”

Finally, the family doctor referred her to a pediatric ophthalmologist. “Beth was about a year old when we first saw Dr. Kushner,” Amy recalls. “Because Beth had astigmatism, she wore glasses, but she still had the head tilt.”

Dr. Kushner scheduled a surgical procedure for strabismus, an eye muscle disorder that caused Beth’s eye to turn or gaze up. “Many children with eye muscle problems will tilt their heads to compensate,” Dr. Kushner said.

“Beth had a muscle imbalance that caused her to tilt her head, to line up the images in her two eyes, which fit with my initial diagnosis.”

However, prior to surgery, after patching one eye to begin to overcome the muscle imbalance, Beth continued to tilt her head. This should have stopped once she was only using one eye to see. “This led me to suspect something else was going on,” Dr. Kushner recalled. “I knew there were other causes for head tilting in children.”

Dr. Kushner ordered a CT scan and the results confirmed the cause was her prematurely fused skull bones.

Although the procedure to correct the muscle could have helped Beth, Dr. Kushner wanted UW Health plastic surgeon Delora Mount, MD, to see Beth for evaluation and possible treatment. Some of the plates on Beth’s skull had fused before she was born, causing her facial features and some underlying muscles to be deformed, which contributed to her “lazy eye.”

“Not too long before surgery was planned, Dr. Kushner called and wanted us to see this other doctor,” Amy says. “I was so frustrated; I just wanted him to do the surgery so we could put it behind us.”

Calling for a consult is the right course of action, Dr. Mount said. “That’s the benefit of having pediatric ophthalmologists,” she said.

“Dr. Kushner recognized the problem because of his vast experience.”

The reconstruction, which Dr. Mount performed with her colleague, UW Health pediatric neurosurgeon Bermans J. Iskandar, MD, is a significant procedure, she continued.

“The correction will enhance her quality of life by making sure she achieves facial symmetry in the future.”

For Amy, Beth’s facial deformity was part of her. But now that her head shape is more symmetrical, it’s Beth that shines through rather than her deformity. Most children who need this surgical procedure are younger than Beth, Dr. Mount said.

Delora Mount, MD, and Bermans Iskandar, MD, pose with Beth Kunz before her surgery.


Beth Kunz looks at a book with Burton Kushner, MD, her favorite among many doctors she has seen.

“The relationship between pediatric ophthalmology, neurosurgery

and plastic surgery is key”

- delora mount, md

The average age is between 6 months and a year. Beth was older, so the process was harder but the results were still positive.

Recently, Beth had one more surgical procedure, with pediatric ophthalmologist Yasmin Bradfield, MD. This is the procedure Amy expected more than a year ago.

“I’m so grateful that Dr. Kushner sent us to Dr. Mount, and that we are close to the UW to get this kind of care,” she said. “He could have done the procedure and then figured

out that she needed the other one,” Amy said. “Instead, he sent us to the right place.”

“Doing strabismus surgery without correcting the underlying problem could have required an additional procedure,” Dr. Kushner said. “If we fixed the eye muscle problem, the muscles may have been changed during the cranial surgery. Then we may have had to do another procedure after.”

The relationship between pediatric ophthalmology, neurosurgery and plastic

surgery is key, Dr. Mount said. She has shared many patients with Dr. Kushner over the years, she added.

For parents, and patients, the seamless working relationship makes things a lot easier, Amy said. “We thought it was just great,” she said. “And Beth, who has seen so many doctors over her short life, loves every one of them.”

But at home, Beth refers to all her doctors as “Dr. Kushner.” :

A nurse prepares Beth Kunz for her cranial surgery.


education

8

TRAINING NEW PHYSICIANS PART OF ACADEMIC MISSION

Teaching aspiring physicians is a significant core mission of the University of Wisconsin Department of Ophthalmology and Visual Sciences. Each July, three medical doctors who have completed their first year of training join six other residents on the path to becoming proficient physicians able to practice high-quality ophthalmology.

Dan Knoch, MD remembers his experience as a resident. Now a comprehensive ophthalmologist, Dr. Knoch attended the University of Wisconsin School of Medicine and Public Health. His mentors here taught him how to be a physician, he said.

“A lot of being a physician is modeling,” Dr. Knoch said. “During residency, you see how physicians act; you see their caring, their dedication to patients, their dedication to learning and to a high standard of care.”

Dr. Knoch decided to stay on at the UW Department of Ophthalmology and Visual Sciences because he had enjoyed his training experience here and he knew he wanted to teach other residents and be able to return the contribution of teaching to upcoming ophthalmologists.

Teaching medicine is different in important ways from providing health care in a private practice, he continued. “You want to always put the patient first in both situations,” he said

“Here, you need to actively involve the resident but make sure the outcome is the same as if the attending physician were providing the care.”

UNDERGOING CHANGES

The University of Wisconsin Department of Ophthalmology and Visual Sciences’ residency program is in the process of undergoing major changes. These changes are required by the governing board of Accreditation Council for Graduate Medical Education, the ACGME. All other academic ophthalmology departments are also required to make changes to their residency programs.

Although residents already receive high-quality training, the changes are designed to go a step further and promote continuous progress in the way residents are trained, said Yasmin Bradfield, MD, a pediatric ophthalmologist and director of the residency program.

“It’s not a matter of doing things differently,” she said. “We already train residents very well. We are being asked to be able to demonstrate the quality of our training program.”

Demonstrating the effectiveness of the program is important, said Stephen Sauer, MD, a comprehensive ophthalmologist and director of residency core competencies in the Department.

“It’s important for those who have a stake in the quality of medicine to know we are doing our job in training,” he said. These stakeholders include not only patients, but the government and other entities that pay for medical care.

“This is a paradigm shift,” Dr. Sauer said. “In the past, we looked at how many surgeries a resident performed. Now it’s not just how many surgeries a resident performs; it’s how well the resident performs those surgeries.”

Attending physicians who trained residents have always considered the quality of their students. This more formalized requirement means that all involved can know, objectively, that the resident is meeting the benchmarks set for seven key areas of medical care.

r e s i d e n c y p rogr am

Chief Resident Amy Badger, MD, right, checks a patient’s vision while Yasmin Bradfield, MD, pediatric ophthalmologist and director of the Residency Program, looks on.

2008 ANNUAL REPORT 9Yasmin Bradfield, MD, a pediatric ophthalmologist, talks with Amy Badger, MD, chief resident, Daniel Knoch, MD, a comprehensive ophthalmologist, and first-year resident Shahed Gloghawala, MD. Pediatric ophthalmology is one of the services residents work in during their three years in the Department.

UW DEPARTMENT OF OPHTHALMOLOGY AND VISUAL SCIENCES10

educationEACH PROGRAM DEVELOPS ITS OWN SYSTEM

The ACGME has required each residency program to develop its own system for tracking progress in six core competencies, which are medical knowledge, patient care, professionalism, interpersonal and communication skills, systems-based practice and practice-based learning and improvement (the American Board of Ophthalmology added surgery as a seventh competency for ophthalmology residents), but has left it open how departments put it into operation. Dr. Sauer believes it will be best achieved by focusing on competency metrics. “I see my role to develop and implement assessment tools to show that residents are competent,” Dr. Sauer said. Not so coincidentally, this focus is a natural fit for Dr. Sauer, who already developed an assessment tool to help track residents’ surgical performance at the Veteran’s Administration Hospital in Madison.

Dr. Sauer created a tool specifically to evaluate the surgical competency of second and third year residents who perform cataract surgery. This assessment tool allows the resident to see both objective and subjective data that assists them in evaluating their level of performance relative to previously discussed benchmarks. This allows the resident time to improve and allows each attending physician the opportunity to assist the resident in improvement. By linking the appropriate competency to an established benchmark for the desired outcome, the assessment tool can assist in creating an

improvement plan for residents who are not meeting the established criteria.

The computer-based tool tracks items such as complications encountered during surgery and Dr. Sauer completes the form after each surgery. Each resident also receives a summary of each surgery. “I fill it out after every case so I can demonstrate to myself and the resident how the resident performed. I don’t have to go from memory at the end of a rotation,” Dr. Sauer said.

Residents receive ongoing feedback on performance throughout the residency program in each specialized area of ophthalmology – retina, glaucoma, pediatrics, comprehensive, cornea, pathology, oculoplastics and neuro-ophthalmology. In the past, residents received informal feedback during each rotation. Formal reviews came at the end of each completed rotation. Each area of the program itself also will improve, Dr. Sauer continued. If residents

struggle with certain areas, the faculty will assess how to change their teaching to better achieve the desired outcomes.

In the end, focusing on core competencies will not only provide residents with timely feedback on their work but also require that attending physicians identify the specific outcomes that the resident must achieve. Faculty must then teach and model a way for the resident to reach the benchmarks that they establish.

Benchmarks for each competency vary. A requirement for many of the competencies is that a resident must pass the national board exam with an acceptable passing or qualifying grade. For others, such as professionalism and interpersonal and communication skills, the measurement will consider how well the resident works with patients and other staff. These evaluations are based on feedback from collaborating physicians, technicians, patients and other affiliated staff.

Dr. Bradfield has added the resident portfolio as an assessment tool. This tool assists in documenting the progress of every resident in each of the core competencies in the individual resident’s portfolio. Dr. Bradfield uses this portfolio when evaluating the performance of the resident.

Although all physicians work with and train residents, it is up to Dr. Bradfield to ensure the residency program is meeting its goals for graduating high quality physicians. “Our ultimate goal is to make sure they get the education they need to be successful,” she said. :

Stephen Sauer, MD, director of residency core competencies, shows an incision during a videotaped eye surgery. Residents may watch surgery from a conference room live or archived. Dr. Sauer is showing an incision on a large-screen television. In the eye, the incision is about the thickness of three dimes stacked together.

continued

2008 ANNUAL REPORT 11Stephen Sauer, MD, goes over a surgery with Frank Hwang, a second-year resident. They are using a computerized tool that helps evaluate the surgical competence of second- and third-year residents performing cataract surgery at the Veterans Administration Hospital in Madison.


research

12

a c h a n c e t o c h a ng e t h e wor l d

COMPLEx D ISEASE CALLS FOR COLLAbORAT ION ACROSS D ISC IPL INES

As a clinical veterinarian, Gillian McLellan, BVMS, PhD, DipACVO, has cared for a variety of animals. Working at the Iowa State School of Veterinary Medicine in Ames, Dr. McLellan specialized in ophthalmology, treating furred and feathered patients with eye diseases including cataracts and glaucoma.

But when she treated two beautiful Siamese cats within a short time of each other, both with an unusual form of glaucoma, the scientist in Dr. McLellan needed to know more. With the help of local veterinarians, she tracked down the pet shop where the animals had been purchased and eventually found the parents of both of her patients.

Fortunately, neither mother nor father had been spayed or neutered, so they could continue to breed. “Oftentimes, people spay and neuter their pets before an inherited health problem has a chance to manifest,” Dr. McLellan said. That’s important for controlling animal population, but it makes research into important diseases challenging. In fact, the owners had more than a dozen offspring from the pair – and all had glaucoma. This was a find that can make clinician scientists like McLellan stop and catch their breath, because the occurrence of a genetically inherited form of glaucoma in animals is remarkably rare.

Dr. McLellan brought the cats to the animal facility in Iowa, where she established a colony of offspring. The cats provide an animal model of glaucoma, which is a sight-stealing disease in humans and other animals. These cats have elevated eye pressures and damage to the optic nerve at a very early age. The cats, who are social creatures and a pleasure to work with, are contributing to treatments for

humans and for other animals, Dr. McLellan said. Studying them, she predicts, will provide unique insights into understanding the causes of human congenital glaucoma, a form of the disease that affects very young children.

Dr. McLellan and her cats moved to the University of Wisconsin in 2006. As a glaucoma researcher, she collaborates with a variety of colleagues investigating the disease, including clinical researchers working on the human form of the disease, other veterinarians and bench scientists.

“If you’re doing glaucoma research, this is one of the top places to be because we share ideas and work together,” she said.

This kind of collaboration between veterinarians, physicians and other scientists is what makes the University of Wisconsin Department of Ophthalmology and Visual Sciences Glaucoma Research Group special.

As a young researcher, Dr. McLellan is mentored by a team of experienced clinicians and scientists in the glaucoma research group, with overall supervision by Robert Nickells, PhD, a scientist who has been studying cell death in this disease for nearly two decades. Glaucoma is characterized by ganglion cell death, which breaks the communication between the eyes and the brain. This is the fundamental cause of vision loss in this prevalent, blinding disease.

Gillian McLellan, BVMS, PhD., holds Willow, a kitten with a rare inherited form of glaucoma. Dr. McLellan came upon a family of cats with this form of glaucoma and is able to study the disease in the animals.It is hoped that this will help find treatments for the disease in humans as well.

2008 ANNUAL REPORT 13Dr. McLellan examines Willow’s eye with an ophthalmoscope. Cats are useful for study because their globes are similar size to humans and the disease does not cause them pain.


COLLAbORAT ION bETWEEN CL IN IC IANS AND SC IENT ISTS IS kEY

Researchers are driven to ask interesting questions and follow the answers to their logical end. Those answers generate new questions, and research scientists follow those as well, said Gregg Heatley, MD, a glaucoma specialist at the UW Department of Ophthalmology and Visual Sciences. “The scientists here at the UW are asking questions

no one has asked before,” Dr. Heatley said. “Each answer brings more questions, which can lead them off into interesting, important work. But sometimes, we need to remind them that although all of the questions are interesting, we need to focus on answers that will improve the options we have to treat human patients with glaucoma.”

Dr. Nickells agreed. “We are a good complement to each other,” he said. “We (basic scientists) can provide a better understanding of the process of disease and we can work on developing methods to test for damage before current technology can find it, but we need the clinicians prodding us for better answers. It helps us keep focused.”

Dr. Nickells said he didn’t know much about glaucoma before he described the specific cell death that occurs in the disease. “I have the real benefit of clinicians who want to do research,” he said. “It’s been a happy marriage.”

By meeting regularly to discuss research projects and clinical issues, the complementary relationship of clinicians and scientists is maintained. “I take great pride in seeing my colleagues answering those basic questions,” Dr. Heatley said.

Although successful research takes a long time, starting with the clinical perspective helps keep scientists focused on the end goal

– preventing and treating vision-threatening

disease. “We do better science because of our formal collaboration with physicians,” Dr. Nickells said. “You can’t do good glaucoma research without input from the clinical side. And they are very supportive of basic science.”

The members of the glaucoma group are synergistic, Dr. Heatley said. “We accomplish much more than anyone could do alone,” he said. “I get excited by the thought that by the time I’m done with my career, the research of our team might have made a very big difference.

“This is a chance to change the world.” :

continuedresearch

Gregg Heatley, MD, checks the eye pressure on a mouse. Dr. Heatley is a glaucoma specialist and often collaborates with other researchers to study the disease.

Gregg Heatley, MD, checks a mouse’s eye pressure in Robert Nickells’ lab.


“This is a chance to change the

world.”

- gregg heatley, md

Gregg Heatley, MD, and Robert Nickells, PhD., look over information from a glaucoma treatment study they collaborated on. At right, Dr. Nickells holds a mouse before checking its eye pressure.


donors

16

FINDING ANSWERS IN RESEARCH

David Walsh and his family have been friends to the University of Wisconsin for decades. David’s father, John J. Walsh, was the legendary boxing coach who won eight national championships. He also earned his law degree here. David earned his bachelor’s degree in business administration at Wisconsin, then joined the U.S. Navy and graduated from Harvard Law School. He is a partner with Foley & Lardner, a national law firm.

David served as president of the UW Board of Regents from 2005-2007 and was recently reappointed to the Board for an additional seven years by Governor Doyle. He has led the University through trying fiscal times while supporting the high quality and accessible education for which the UW is known.

But the Walsh family’s connection to the UW is even more personal. David and his wife, Nancy, have two children who were born hearing impaired. During their mid-teens, the family learned the boys have Usher Syndrome, which results from one of a number of gene defects that leads to both deafness and blindness. At the same time, Nancy was diagnosed with progressive multiple sclerosis.

Rather than complain about the results of their genetic lottery, the Walshes have put their

amazing energy to work in support of research into blinding diseases. David serves on the board of The Foundation Fighting Blindness, a major national foundation dedicated to funding and advancing retinal research. He is also chair of the University of Wisconsin Hospital & Clinics Authority Board and chair of the Advisory Board of the Alice R. McPherson UW-Madison Eye Research Institute. As such, he was able to encourage a young UW Department of Ophthalmology and Visual Sciences researcher, David Gamm, MD, PhD., to apply for a grant to fund early research.

At first Dr. Gamm was reluctant. “At that point in my career, I had limited experience in stem cell research,” he said. “I was in the early stages of setting up my lab and writing grants to support my work. I knew what I wanted to do, but wasn’t sure how to make it happen.”

David Walsh provided more than just a resource to receive a grant. He provided a face for the patients Dr. Gamm hoped to help with his research. “At first, I didn’t have many patients with degenerative retinal disease,” he said “Now that I’ve been practicing for a number of years,

I do, but Dave (Walsh) was able to personalize my lab’s efforts from the very beginning. He emphasized the importance of our work and infused a tremendous amount of enthusiasm.”

David and Nancy don’t think their support was all that unusual. They knew the Foundation wanted to support researchers studying retinal degenerative diseases. They knew the University of Wisconsin. And they hoped they could help bring the research support to the UW.

“It was about the time stem cells were becoming a hot issue and there was no eye research of this type in the Midwest,” Walsh recalled. “We wanted to help promote eye research with a match.”

“I think he was poised to act quickly and efficiently,” Dr. Gamm said. “He was waiting for someone to propose this kind of project so he could support it.”

Rather than simply supporting Dr. Gamm, however, David and Dr. Gamm also lobbied to create an infrastructure for retinal stem cell research nationwide. So although he was able to hire a technician with the funds that went to his laboratory, some of David Walsh’s support went to Dr. Gamm’s collaborators at other institutions as well.

“That gave me an instant group of people I could learn from and work with,” Dr. Gamm said. “The forethought that took on David’s part was incredible.”

w a l s h e s s u p por t v i s i o n r e s e a r ch

David Gamm, MD, PhD


“There is a lot going on here. We’re building on that to make something even

better.”

- david walsh

Dr. Gamm continues to collaborate with researchers within and outside the University of Wisconsin and his relationship with David Walsh has grown as well. “His integrity has been a great example to me,” Dr. Gamm said.

“Dave interacts with people in a straightforward, honest way,” Dr. Gamm said. “I try to emulate that in my encounters as well.”

Many people who support researchers would be inclined to seek answers to their personal questions. But David Walsh celebrates any advances Dr. Gamm makes. “Even when we make advances that are not directly connected with Usher’s disease, where Dave has such a

personal connection, he gets as excited as we do. He sees that it’s all connected,” Dr. Gamm said.

“He knows what he wants to get done for the good of his family, the University, the state and the country. He doesn’t have a personal agenda, even though he has every right to have one.”

David Walsh said his fundraising work has evolved as his understanding of research has increased.

“We realize that blindness isn’t cancer, it isn’t killing people,” Walsh said. “It doesn’t get the attention. It’s great to help someone like Dr. Gamm who has been able to find answers to our questions.” But the work continues.

“I think the UW Department of Ophthalmology and Visual Sciences needs to be more boastful,” Walsh said. This is ironic given that Walsh, who has been active on many levels, is rarely boastful about himself.

“I came back to Madison,” Walsh said. “I gave up Wall Street to come home. This is my home, my community, our family. I’m interested in this research because of them. I want to move the ball and what a great place to do it. I get to be part of the excitement.

“There is a lot going on here. We’re building on that to make something even better.” :

John Walsh, who was born with Usher syndrome, visits with his parents Nancy and David. Nancy and David Walsh (above right) and their son, John, chat with David Gamm MD, PhD, a researcher the Walsh family supports.


CLINICAL RESEARCH FACULTY & STAFF 2008-2009

18

Michael Feifarek, MD InstructorComprehensive ophthalmology

David M. Gamm, MD, PhDAssistant ProfessorPediatric ophthalmology & strabismus, retinopathy of prematurity, pediatric cataract surgery & intraocular lens implantation, pediatric glaucoma

Thomas D. France, MDProfessor Emeritus*Pediatric ophthalmology & strabismus, amblyopia, visual function testing

Justin L. Gottlieb, MDAssociate ProfessorRetina, vitreous, macula

Gregg A. Heatley, MDAssociate ProfessorVice-Chair/ClinicalGlaucoma, anterior segment & cataract surgery

Celeste K. Jend, ODClinical OptometristOptometry

Michael S. Ip, MDAssociate ProfessorRetina, vitreous, macula

Ronald E. Kalil, PhDProfessorNeural cell death & repair after brain damage

Ronald L. Engerman, PhDProfessor Emeritus*Diabetic retinopathy & microangiopathy, animal models, biology of microvasculature

Ivy J. Dreizin, MDAssociate Professor Neuro-ophthalmology

Paul L. Kaufman, MDPeter A. Duehr Professor & ChairGlaucoma, aqueous humor dynamics, anterior segment physiology & pharmacology, presbyopia

* emeritus

Barbara E.K. Klein, MD, MPHProfessorGlaucoma, comprehensive ophthalmology, cataracts, diabetic retinopathy, epidemiology, preventive medicine

Richard E. Appen, MD Professor Emeritus*Neuro-ophthalmology

Michael M. Altaweel, MDAssociate ProfessorRetina, vitreous, macula, ocular melanoma

Daniel M. Albert, MD, MSFrederick Allison Davis and Lorenz E. ZimmermanProfessor & Chair Emeritus Ocular oncology, ophthalmic pathology, comprehensive ophthalmology

Eugene D. Cropp, OD Clinical Optometrist Optometry

Ronald P. Danis, MDProfessor, Director of the Fundus PhotographReading Center Macular degeneration, diabetic retinopathy, retinal vascular diseases & posterior ocularinflammatory disorders

Janet Cushing, OD Clinical Optometrist Optometry

Karen J. Cruickshanks, PhD Professor Epidemiology of age-related ocular disorders, hearing loss, diabetes

Richard K. Dortzbach, MDProfessor Emeritus*Ophthalmic plastic & reconstructive surgery, surgical techniques

Matthew D. Davis, MD Professor Emeritus* Vitreoretinal disease, diabetic retinopathy, clinical trials

Nansi Jo Colley, PhD Professor Molecular/genetic studies of retinal degeneration in Drosophila

Suresh R. Chandra, MD Professor Vitreoretinal disease, macular disease, ocular melanoma, trauma, international ophthalmology

Cat N. Burkat, MDAssistant ProfessorOphthalmic reconstructive & cosmetic surgery

Curtis R. Brandt, PhDProfessor Virology, cell & molecular biology, genetic mapping & recombinant techniques, gene therapy

Yasmin S. Bradfield, MDAssociate ProfessorResidency DirectorPediatric ophthalmology & strabismus, retinopathy of prematurity, pediatric cataract surgery & intraocular lens implantation, pediatric eyelid surgery, pediatric glaucoma

Barbara A. Blodi, MD Associate Professor Retina, vitreous, macula

Neal P. Barney, MDAssociate Professor Cornea & externaldisease, cornea & cataract surgery, uveitis, ocular immunology

Julia Agapov, MD, DOAssistant ProfessorGlaucoma, anterior segment & cataract surgery

Yonca Arat, MDAssistant ProfessorComprehensive ophthalmology, cataract surgery


Stephen K. Sauer, MDAssistant ProfessorComprehensive ophthalmology, cataract surgery

T. Michael Nork, MD, MSAssociate ProfessorDiseases & surgery of the retina & vitreous

Robert W. Nickells, PhDProfessor Vice-Chair/ResearchMolecular biology of cell death in glaucoma & retinoblastoma

Todd W. Perkins, MDProfessorGlaucoma, normal tension glaucoma, implant devices, cataract surgery

Heather A.D. Potter, MDAssistant ProfessorComprehensive ophthalmology, ophthalmic pathology,cataract surgery

Arthur S. Polans, PhDProfessor Cancer-related ocular pathologies

Patricia C. Sabb, MDAssistant ProfessorComprehensive ophthalmology, cataract surgery, refractive surgery

Brian Puent, ODClinical Optometrist

Sarah M. Nehls, MDAssistant Professor Vice-Chair/CME & Faculty DevelopmentRefractive surgery, cornea & external disease, cornea & cataract surgery, uveitis

Burton J. Kushner, MDProfessorPediatric ophthalmology & strabismus, amblyopia, surgical techniques

Michele M. Martin, ODClinical OptometristOptometry

Julie A. Mares, PhDProfessorEpidemiology of eye disease, nutritional epidemiology

Mark J. Lucarelli, MDAssociate ProfessorOphthalmic plastic surgery

Leonard A. Levin, MD, PhDProfessorNeuro-ophthalmology, ganglion cell death

Ronald Klein, MD, MPHProfessorVitreoretinal disease, diabetic retinopathy,age-related eye diseases, epidemiology

Daniel W. Knoch, MDAssistant ProfessorComprehensive ophthalmology, cataract surgery

Amy L. Walker, ODClinical OptometristOptometry

James N. Ver Hoeve, PhDSenior ScientistVisual electrophysiology

Norbert F. Toussaint, Jr., MDAssistant ProfessorComprehensive ophthalmology, cataracts

Andrew T. Thliveris, PhD, MDAssociate Professor Chief of Ophthalmology William S. Middleton Memorial Veterans Hospital Comprehensive ophthalmology, cataracts, ocular genetics

John E. Temprano, MDAssociate ProfessorComprehensive ophthalmology, cataract surgery

Michael C. Struck, MDAssociate ProfessorPediatric ophthalmology & strabismus, retinopathy of prematurity, pediatric cataract surgery & intraocular lens implantation, pediatric glaucoma

Thomas S. Stevens, MDProfessorVitreoretinal disease, macular disease, diabetic retinopathy, proliferative vitreoretinopathy

Gary W. Sterken, MDAssistant ProfessorComprehensive ophthalmology, cataract surgery, glaucoma

Nader Sheibani, PhDAssociate ProfessorDiabetic retinopathy, retinopathy of prematurity, animal models and retinal vascular cell biology and signal transduction


2008 CLINICAL TRIALS

20

A Natural History Study of Macular Telangiectasia: The Mactel Study – Mactel

Principal Investigator: Barbara Blodi, MD

Study Coordinator: Shelly Olson

Synopsis:This study is a prospective, cross-sectional study of participants with a diagnosis of macular telangiectasia. At least 200 participants will be enrolled and all affected subjects will undergo examinations. A complete family history will be solicited. First-degree relatives (primary siblings, secondary parents) of the participants will be actively recruited and asked to contribute a blood sample for genetic genotyping and analysis of markers of systemic disease, as well as undergo a complete ophthalmologic examination.

Participants’ genetic information (including issues of adoption and paternity, which may be discovered from this study) will not be revealed to other family members or other people. Only in the unlikely situation in which such information has direct medical implications for the participant or his/her family will these issues be discussed with the participant. Published information regarding the participant’s family tree will keep the identity of the participant and family members coded so as to maintain confidentiality.

Age-Related Eye Disease Study 2 (AREDS 2)

Principal Investigators: Suresh Chandra, MD, and Barbara Blodi, MD

Study Coordinator: Shelly Olson

Synopsis:A multi-center, randomized trial of lutein, zeaxanthin, and omega-3 long-chain polyunsaturated fatty acids [docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)] in age-related macular degeneration.

The primary objective is to see whether nutritional pills with lutein and zeaxanthin and/or omega-3 long-chain polyunsaturated fatty acids, specifically docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), have a beneficial effect on AMD when compared to placebo.

There will be four study treatment groups:

Lutein/zeaxanthin and a placebo that • resembles the DHA/EPA pill.

DHA/EPA and a placebo that resembles • the lutein/zeaxanthin pill.

Lutein/zeaxanthin and DHA/EPA.•

Placebos resembling the lutein/zeaxanthin • pills and the DHA/EPA pills.

We will be recruiting approximately 150 patients here at the UW. Approximately 4,000 people will participate in this study at various medical centers in the United States. Patient participation will last until 2012 and will require two visits in the first three months of the study and then one visit each year for the remainder of the study. At three months and six months after the second visit during the first year and then every six months in between study visits, patients will also receive a phone call.

Allergan

Principal Investigator: Michael Altaweel, MD

Study Coordinator: Angie Wealti

Synopsis: The purpose of this study is to evaluate the safety and efficacy of DEX as adjunctive therapy to Lucentis compared with sham DEX plus Lucentis in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

This study will be conducted in 2 cohorts of patients with CNV secondary to AMD. Cohort 1 will consist of patients who have never received treatment for AMD in the study eye. Cohort 2 will consist of patients who have previously received treatment for AMD in the study eye. The enrollment for both cohorts will start simultaneously, and each cohort will enroll approximately 100 patients.

Brainport

Principal Investigator: Michael Ip, MD

Study Coordinator: Barbara Soderling

Synopsis:The primary outcome of this study will be to test the ability of the HMI prototype device, following the proper training, to improve visual function in patients. A variety of function tests will be performed. Additional outcomes of this proposal include the ease of use of the prototype device and acceptability of the device from the patient’s perspective (cosmesis).

Comparison of AMD Treatment Trials (CATT) Lucentis – Avastin Trial

Principal Investigators: Suresh Chandra, MD and Michael Altaweel, MD

Study Coordinators: Kris Dietzman, Angie Wealti, Jennie Perry-Raymond

Synopsis:This study seeks to evaluate the relative efficacy and safety of treatment of subfoveal neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a variable schedule, and Avastin on a variable schedule.


CNV Secondary to AMD Treated with Beta RadiatioN Epiretinal Therapy – NeoVista Inc. (CABERNET): NV1-114 Randomized, Prospective, Controlled Study of the NeoVista System for the Treatment of Subfoveal Choroidal Neovascularization Associated with Wet AMD

Principal Investigator: Michael Ip, MD

Study Coordinators: Kris Dietzman and Guy Somers, RN

Synopsis:The objective of the CABERNET Trial is to evaluate the safety and efficacy of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) associated with wet age-related macular degeneration (AMD). The CABERNET Trial is a randomized, prospective, controlled study of the Epi-Rad90 TM Ophthalmic System for the treatment of subfoveal choroidal neovascularization associated with wet age-related macular degeneration.

Diabetic Retinopathy Clinical Research Network (DRCR)

A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema

Principal Investigator: Justin Gottlieb, MD

Study Coordinator: Kathryn Burke

Synopsis:To determine whether intravitreal triamcinolone acetonide injections at doses of 1 mg or 4 mg produce greater benefit, with an acceptable safety profile, than macular laser photocoagulation in the treatment of diabetic macular edema.

To compare the efficacy and safety of the 1 mg and 4 mg triamcinolone acetonide doses.

STUDY I: Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination with Laser Photocoagulation for Diabetic Macular Edema



Synopsis:The purpose of the study is to compare: 1) sham injection plus laser treatment; 2) injection of intravitreal ranibizumab (Lucentis) plus laser treatment; 3) injection of intravitreal ranibizumab plus deferred (or delayed) laser treatment; or 4) injection of intravitreal triamcinolone plus laser treatment. It is a three-year study with follow-up every four weeks. During years 2 and 3, follow-up visits will be every four weeks as long as injections of the study drug are still being given. Once injections are no longer given, follow-up will be every four months.

Recruitment/Eligibility:Recruitment is open. For more information, contact Kathryn Burke at (608) 263-7172.

STUDY J: Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation (PRP) for Proliferative Diabetic Retinopathy



Synopsis:This study is being conducted to determine whether ranibizumab (Lucentis) or triamcinolone acetonide will benefit patients following PRP. All patients will receive focal and panretinal (full scatter) photocoagulation and be randomly assigned to one of the following three injection groups: 1) Intravitreal injection of ranibizumab at baseline and four weeks; 2) Intravitreal injection of triamcinolone acetonide at baseline and sham injection at four weeks; 3) Sham injection at baseline and four weeks. It is a 56-week study, in which patients will receive focal and PRP within 14 days of injection (can complete up to three PRP sessions within 49 days), with three additional visits at 14, 34, and 56 weeks.

STUDY K: The Course of Response to Focal Photocoagulation for Diabetic Macular Edema (DME)



Synopsis:The study objective is to determine the course of changes in optical coherence tomography (OCT)-measured macular thickness and visual acuity (VA) following a single session of focal photocoagulation for center-involved DME. The response will be evaluated separately in eyes with and without prior focal photocoagulation for DME. The purpose is to determine the proportion of eyes that continue to improve at least 5 letters in VA or at least 10 percent in central retinal thickness after a session of focal photocoagulation. Follow-up visits for all subjects at eight weeks and 16 weeks. Treatment is to be deferred and follow-up is continued as long as VA has improved by 5 letters or OCT central subfield has decreased by 10 percent compared with baseline. Follow-up ends for eyes that receive additional treatment.

Evaluation of Vitrectomy for Diabetic Macular Edema Study



Synopsis:The purpose of the study is to collect information about the effectiveness of vitrectomy in patients diagnosed with diabetic macular edema who are treated with standard therapy. Patients will be examined before vitrectomy, and then follow-ups will be performed at 3, 6, 12, 24, and 36 months.


2008 CLINICAL TRIALS

22

Expression of Inflammatory Mediators in Allergic Conjunctivitis

Principal Investigator: Neal Barney, MD

Study Coordinator: Barbara Soderling

Synopsis:The purpose of this study is to determine which inflammatory substances are involved in causing allergic symptoms in the eye. Allergic conjunctivitis is a common problem, with symptoms of temporary redness, itching, tearing, and swelling of the eyes. Substances released by cells in the affected tissues cause allergic reactions in the eye and elsewhere in the body.

Fellow Eye Changes After Unilateral Avastin Injection for Bilateral Diabetic Macular Edema – FEAD ME

Principal Investigator: Jon Gunther, MD

Study Coordinator: Kris Dietzman

Synopsis:This study will evaluate the effect of monocular intravitreal injection of bevacizumab (Avastin) on the fellow eye in patients with bilateral diabetic macular edema as measured with optical coherence tomography (OCT), best corrected visual acuity (BCVA), and fundus photography. It also will evaluate the effect on OCT, BCVA, and fundus photography of intravitreal injection of bevacizumab in the injected eye.

Health Measurement in Patients: Tracking Clinical Outcomes (Cataract Study)

Principal Investigator: Neal Barney, MD

Study Coordinator: Kris Dietzman

Synopsis:The overall goal of this program of research is to create a versatile “toolbox” of summary measures of health-related quality of life that can be used by health care professionals, policy-makers, and researchers in the United States to track the health of the public, over time and across different subgroups of population. The focus of this project is to evaluate the sensitivity of these various measures to clinical outcomes among groups of patients.

Molecular Prognostic Assay for Uveal Melanoma


Study Coordinator: Guy Somers, RN

Synopsis:This study will investigate the accuracy of a molecular test for predicting metastasis in uveal melanoma patients. This may lead to better prognostic testing and prophylactic treatment for high-risk patients.

OPHTEC – Model 311 Artificial Iris Lens for the Treatment of Visual Disturbances Resulting from Partial or Total Absence of the Human Iris: Continued Access Compassionate Use Study


Study Coordinators: Kris Dietzman, Jennie Perry-Raymond

Synopsis:OPHTEC’s Model 311 Artificial Iris Intraocular Lens is a unique, single-piece lens manufactured from colored, ultraviolet light absorbing polymethylmethacrylate (PMMA). The lens is designed for implantation into an aphakic human eye for the correction of visual disturbances resulting from an incomplete or totally absent iris and the correction of the spherical refractive error as necessary. The lens is available in three colors;

brown, blue, and green. Available powers range from +10.0 to +30.0 diopters in 0.5 diopter increments or without power (plano). The colored portion of the lens is 9.0 mm in diameter, while the central clear optic is 4.0 mm in diameter. The optic configuration is bi-convex and the anterior to posterior radius is dependent on lens power. The lens has two C-loop haptics, each with an eyelet at the haptic apex to provide the option to suture fixate the lens. The overall diameter of the lens is 13.75 mm (uncompressed haptic to haptic).

The objective of this study is to provide continuing access to the Model 311 Artificial Iris Lens during the preparation and FDA review of the Humanitarian Use Device Application. The sponsor has provided FDA with sufficient safety data for the lens to justify continued access during the FDA registration process.

The objective of this Continued Access phase of the study is to collect additional safety data on a larger population that may provide further insight regarding potential complications that may occur at low rates not necessarily detected in the primary study for this device.

Pediatric Eye Disease Investigator Group (PEDIG)

Residual Amblyopia Treatment Study (A11)

Principal Investigator: Yasmin Bradfield, MD

Study Coordinators: Barbara Soderling, Kris Dietzman

Synopsis: This study is designed to evaluate the effectiveness of treatment of residual amblyopia in children ages 3 to <8 years with visual acuity of 20/32 to 20/50 in the amblyopic eye. The study is a randomized clinical trial comparing intensive treatment (8 hours of daily patching plus daily atropine) with a control group that will have rapid weaning of existing treatment followed by spectacle correction only (if needed). The primary objective is to determine if intensive treatment will improve visual acuity in patients with residual amblyopia.


Regeneron: A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration (VGFT-OD-0605)


Study Coordinators: Angie Wealti, Kris Dietzman, Jennie Perry-Raymond

Synopsis: The purpose of this study is to assess the efficacy of intravitreal (ITV) administered VEGF Trap compared to ranibizumab in a non-inferiority paradigm in preventing moderate vision loss in subjects with all subtypes of neovascular AMD.

The Standard Care vs. Corticosteroid for Retinal Vein Occlusion Study (SCORE)


Study Coordinator: Jenny Perry-Raymond

Synopsis:This study has two randomized trials to compare the efficacy and safety of intravitreal injection(s) of triamcinolone acetonide with standard care to treat macular edema: one for central vein occlusion and one for branch retinal vein occlusion. The primary efficacy outcome of this study is improvement by 15 or more letters from baseline in best-corrected ETDRS visual acuity score at the 12-month visit as determined by the ETDRS visual acuity protocol. The primary outcome analysis will include the following three comparisons of the proportion of participants having a 15 ETDRS letter improvement from baseline to year 1: 1) 4 mg triamcinolone acetonide intravitreal injections with standard of care; 2) 1 mg triamcinolone acetonide intravitreal injections with standard of care; 3) 4 mg triamcinolone acetonide intravitreal injections with 1 mg triamcinolone acetonide intravitreal injections.

Topcon: Reproducibility of Topcon SC-OCT and Comparison to Stratus TD-OCT

Principal Investigator: Ronald Danis, MD

Study Coordinator: Jennie Perry-Raymond

Synopsis:The development and commercialization of the Time Domain OCT (TD-OCT) over the past 17 years has lead to widespread use of these machines for clinical and research application. Given the lack of competition, the single-source TD-OCT has become commonplace to the extent that the outputs of this instrument and the standardized reports that are generated have extensively guided clinical care and research. The challenge for new OCT technology, Spectral Domain OCT (SD-OCT) now entering the marketplace is to assure physicians that the new instrument has similar reports and measurements with which they are familiar and that the measurements are comparable to the TD-OCT. The SD-OCT is expected to demonstrate less variability of measurements and greater resolution of morphology. A comparison of SD-OCT with TD-OCT is indicated to determine how the measurements and resolution of morphology compare.


2008 AWARDS, LECTURES & PUbLICATIONS

24

Daniel M. Albert, MD, MS

van Ginkel PR, Darjatmoko SR, Sareen D, Subramanian L, Bhattacharya S, Lindstrom MJ, Albert DM, Polans AS. Resveratrol inhibits uveal melanoma tumor growth via early mitochondrial dysfunction. Invest Ophthalmol Vis Sci. 2008;49:1299-1306.

Albert DM, Gangnon RE, Grossniklaus HE, Green WR, Darjatmoko S, Kulkarni AD. A study of histopathological features of latanoprost-treated irides with or without darkening compared with non-latanoprost-treated irides. Arch Ophthalmol. 2008;126(5):626-631.

Avery RB, Diener-West M, Reynolds SM, Grossniklaus HE, Green WR, Albert DM. Histopathologic characteristics of choroidal melanoma in eyes enucleated after Iodine 125 brachytherapy in the Collaborative Ocular Melanoma Study. Arch Ophthalmol. 2008;126:207-212.

Albert DM, Dubielzig RR, Li Y, Lin T, Neekhra A, Orilla W, Ramos M, Salamat MS, Burke JA. Choroidal melanoma occurring in a nonhuman primate: Report of a case. Arch Ophthalmol. 2009. In Press.

Collaborative Ocular Melanoma Study Group. Baseline echographic characteristics of tumors in eyes of patients enrolled in the collaborative ocular melanoma study: COMS report no. 29. Ophthalmology. 2008;115(8):1390-1397.

Michael M. Altaweel, MD

Browning DJ, Altaweel MM, Bressler NM, Bressler SB, Scott IU. Diabetic macular edema: what is focal and what is diffuse? Am J Ophthalmol. 2008;10:1016.

Altaweel MM, Johnson DL. Chapter 130. Optical coherence tomography. In: Albert and Jakobiec’s Principles and Practice of Ophthalmology, 3rd Ed. Eds.: Albert DM, Miller JW, Azar DM, Blodi BA. Elsevier Inc.: London. 2008.

Lecture: Altaweel MM, VerHoeve J, Eells J, Hanzlik R. “Evaluation of Ocular and Systemic Safety of Calcium Formate, a New Calcium Supplement.” The Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale, Fla. May 1, 2008.

Chairman/Speaker: Extraordinary Ophthalmology International Conference. Madison, Wis. July 11-12, 2008.

Co-Chair: Ocular Imaging Conference, American Academy of Ophthalmology Annual Meeting, Atlanta. November 9, 2008.

Neal P. Barney, MD

Cook EB, Stahl JL, Graziano FM, Barney NP. Regulation of the receptor for TNF1, TNFR1, in human conjunctival epithelial cells. Invest Ophthalmol Vis Sci. 2008;49(9):3992-8. Epub ahead of print May 18, 2008.

Medical Director, University Station Eye Clinic. Madison, Wis.

Lecture: “Allergic Eye Disease.” American Academy of Allergy, Asthma and Immunology Annual Fellows Review Course, Toronto. May 14-15, 2008. Lecture: “Allergic Eye Disease,” & “Epithelium: A Common Thread in Ocular Surface Inflammation.” Massachusetts Eye and Ear Infirmary, Boston. September 18-19, 2008.

Barbara A. Blodi, MD

Moeller S, Voland R, Tinker L, Blodi B, Klein M, Gehrs K, Johnson E, Snodderly M, Wallace R, Chappell R, Parekh N, Ritenbaugh C, Mares JA. Associations between age-related nuclear cataract and lutein and zeaxanthin in the diet and rerum in the Carotenoids in Age-Related Eye Disease Study (CAREDS), an ancillary study of the Women’s Health Initiative. Arch Ophthalmol. 2008;126(3):354-364. Associate Editor: Albert and Jakobiec. Priniciples and Practice of Ophthalmology, 3rd Ed. Elsevier Inc.: London. 2008.

Yasmin S. Bradfield, MD

Pediatric Eye Disease Investigator Group. A randomized trial of near versus distance activities while patching for amblyopia in children aged 3 to less than 7 years. Ophthalmology. 2008;115(11):2071-8. Manuscript writing committee.

Instructor: Struck MC, Bradfield YS, France TD. “Atropine Treatment for Amblyopia: Perils and Pitfalls.” Academy of Ophthalmology. Atlanta. November 10, 2008.

Poster: Black B, Felius J, Laroche GR, Bradfield YS, Williams P, Paysse E. Clinical determinants of the impact of strabismus on the quality of life in adults. Annual AAPOS Meeting, Washington, D.C. April 2-6, 2008.

Curtis R. Brandt, PhD

Research Awards

NIH-NEI RO1 EY018597. Virion Sialic Acid and HSV Ocular Infection. Curtis R. Brandt, PI, 9/1/08 to 7/31/12. Total costs $1,485,000.00.

Patents

Brandt CR and Bultmann H. Pharmacologically Active Antiviral Peptides. US Patent Office, Patent No. 7,371,809 B2, May 13, 2008.

Publications

Cai, S and Brandt, CR. 2008. Induction of IL-6 by an attenuated HSV vector in human retinal pigment epithelial cells requires NFκB activation and viral replication. Experimental Eye Res. 86:178-188.

Akkarawongsa, R, Potocky, TB, English, EP, Gellman, SH, and Brandt, CR. 2008. Inhibition of Herpes simplex virus Type 1 Infection by Cationic β-Peptides. Antimicrob. Agents Chemotherap. 52:2120-2129.

Yu, M, Chen, X, Wang, N. Cai, S., Li, N, Qui, J, Brandt, CR, Kaufman, PL, and Liu, X. 2008. H-1152 effects on intraocular pressure and trabecular meshwork morphology of rat eyes. J Ocular Pharmacol Therapeu. 24:373-379.

Suresh R. Chandra, MD

Chandra SR. Global blindness: VISION 2020: The right to sight. Arch Ophthalmol. 2008;26(10):1457.

Lecture: “How Do We Manage Age-Related Macular Degeneration Today?” All India Ophthalmology Society Annual Meeting, Bangalore, India. February 2, 2008.

Co-Instructor: “Management of Posterior Segment Complications-Cataract Surgery.” All India Ophthalmology Society Annual Meeting, Bangalore, India. February 1, 2008.

Co-Instructor: “Two New U.S. National Clinical Trials for ARMD.” All India Ophthalmology Society Annual Meeting, Bangalore, India. February 2, 2008.

Maguire MG, Alexander J, Fine SL. Complications of Age-related macular degeneration Prevention Trial (CAPT) Research Group. Characteristics of choroidal neovascularization in the Complications of Age-related macular degeneration Prevention Trial (CAPT). Ophthalmology. 2008;115:1468-1473.


Nansi Jo Colley, PhD

Lecture: “Fundamental Issues in Visual Research.” Marine Biological Laboratory, Woods Hole, Mass. 2008.

Lecture: International Society of Ocular Cell Biology (ISOCB) Meeting. San Diego. 2008.

Lecture: 49th Annual Drosophila Research Conference, Genetics Society of America, San Diego. 2008.

Grant: Retina Research Foundation Grant: Retinal Degeneration in Drosophila.

Grant: Israel Binational Science Foundation Grant, with Minke B: Calphotin Regulation of the Light Response in Drosophila Photoreceptors. The Hebrew University Faculty of Medicine, Jerusalem.

Karen J. Cruickshanks, PhD

Wiley TL, Chappell R, Carmichael L, Nondahl DM, Cruickshanks KJ. Changes in hearing thresholds over 10 years in older adults. J Am Acad Audiol. 2008;19(4):281-292.

Trentham-Dietz A, Sprague BL, Klein R, Klein B, Cruickshanks KJ, Fryback DG, Hampton JM. Health–related quality of life before and after a breast cancer diagnosis. Breast Cancer Res Treat. 2008;109(2):379-87.

Klein R, Knudtson MD, Cruickshanks KJ, Klein BEK. Further observations on the association between smoking and the long-term incidence and progression of age related macular degeneration: The Beaver Dam Eye Study. Arch Ophthalmol. 2008;126(1)115-21.

Invited Speaker: “Measuring Taste Impairment in Epidemiologic Studies – The Beaver Dam Offspring Study.” International Symposium on Olfaction and Taste, San Francisco. July 21-25, 2008.

Lecture: “As Time Goes By: A Population Perspective on Hearing in Aging.” 20th Anniversary Symposium, National Institute on Deafness and Other Communication Disorders, Washington, D.C. October 23, 2008.

Ronald P. Danis, MD

Danis RP, Fisher MR, Lambert E, Goulding A, Wu D, Lee LY. Results and repeatability of retinal thickness measurements from OCT certification submissions. Arch Ophthalmol. 2008;126(1):45-50.

Danis RP, Domalpally A. Optimizing Stratus OCT3 image and data quality. Review of Ophthalmology. 2008;15:02:87-92.

Danis RP, Bingaman DP. Chapter 5. Neovascularization in models of branch retinal vein occlusion. In: Retinal and Choroidal Angiogenesis. Ed.: Penn JS. Springer Publishers: The Netherlands, 2008

Danis RP. Chapter 134. Diabetic macular edema. In: Principles and Practice of Ophthalmology. Eds.: Albert D, Miller J. Elsevier Inc.: Canada, 2008.

Lecture: “Association of Fluorescein Angiography and OCT in Diabetic Macular Edema.” American Academy of Ophthalmology Annual Meeting, Atlanta. Nov 8-11, 2008.

Thomas D. France, MD

Invited Speaker: “Desarrollo de la Visión en los Niños con Síndrome de Down (Vision Development in Children with Down Syndrome).” Meeting of the Chilean Congress of Ophthalmology, Puerto Varas, Chile. December 8-14, 2008.

Invited Speaker: “Diplopia and Strabismus in Orbital Blow-out Fractures: The Wisconsin Experience.” Meeting of the Chilean Congress of Ophthalmology, Puerto Varas, Chile. December 8-14, 2008.

Invited Speaker: “Accommodative Esotropia: Emetropización en Pacientes con Estropia Acomodativa, Long Term Results.” Meeting of the Chilean Congress of Ophthalmology, Puerto Varas, Chile. December 8-14, 2008.

Invited Speaker: “Treatment of Amblyopia by Optical Penalization.” Meeting of the Chilean Congress of Ophthalmology, Puerto Varas, Chile. December 8-14, 2008.

David M. Gamm, PhD

Gamm DM, Wright LS, Capowski E, Shearer RL, Meyer JS, Kim HJ, Schneider BL, Melvan JN, Svendsen CN. Regulation of prenatal human retinal neurosphere growth and cell fate potential by retinal pigment epithelium and Mash1. Stem Cells. 2008;26(12):3182-3193.

Wang S, Girman S, Lu B, Bischoff N, Holmes T, Shearer R, Wright LS, Svendsen CN, Gamm DM, Lund R. Long term vision rescue by human neural progenitors in a rat model of photoreceptor degeneration. Invest Ophthalmol Vis Sci. 2008;49(7):3201-3206.

Gamm DM, Kulkarni AD, Albert DM. Chapters on retinoblastoma and phakomatoses. In: Pathobiology of Ocular Disease. Eds.: Garner A and Klintworth GK. Taylor & Francis: New York, 2008.

Lecture: Gerald A. Fishman Distinguished Lecturer, University of Illinois at Chicago. May 30, 2008.

Organizer/Speaker: Session on Blinding Diseases. World Stem Cell Summit, Madison, Wis. September 22, 2008.

Michael S. Ip, MD

Ip MS, Scott IU, Brown GC, Brown MM, Ho AC, Huang SS, Recchia FM. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration. Ophthalmology. 2008;115:1837-46.

Ip MS, Bressler SB, Antoszyk AN, Flaxel CJ, Kim JE, Friedman SM, Qin H; Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina. 2008;28(7):919-30.

Lecture: “The Combination of Epiretinal Brachytherapy and Intravitreal Bevacizumab for the Treatment of Neovascular AMD.” Royal Hawaiian Eye Meeting, Waikoloa, HI. January 22, 2008.

Lecture: “Pathophysiology of Diabetic Retinopathy. Advances in Age-Related Macular Degeneration.” University of Pittsburgh. October 4, 2008.

Lecture: “Diabetic Retinopathy: Pathophysiologic Concepts.” 40th Sally Letson Symposium, Ottawa. September 11-13, 2008.


2008 AWARDS, LECTURES & PUbLICATIONS

26

Paul L. Kaufman, MD

Wasilewski R, McDonald JP, Heatley G, Lütjen-Drecoll E, Kaufman PL, Croft MA. Surgical intervention and accommodative responses, II. Invest Ophthalmol Vis Sci. 2008;49:5495-5502.

Kaufman PL. “Enhancing trabecular outflow by disrupting the actin cytoskeleton, increasing uveoscleral outflow with prostaglandins, and understanding the pathophysiology of presbyopia. Interrogating Mother Nature: asking why, asking how, recognizing the signs, following the trail.” The 2006 Ernst H. Bárány Prize Lecture. Exp Eye Res. 2008;86:3-17.

Lecture: “How Shall We Deliver Theraputic Molecules to Targets Within the Eye?” World Ophthalmology Congress 2008, Hong Kong. June 28-July 2, 2008.

Lecture: “ Novel Ways of Controlling IOP.” World Ophthalmology Congress 2008, Hong Kong. June 28-July 2, 2008.

Invited Speaker: “Medical Therapy for Glaucoma: The Next 20 Years.” Kyoto Prefecural University, Department of Ophthalmology, Kyoto, Japan. August 4, 2008.

Barbara E. K. Klein, MD, MPH

Klein BEK, Klein R, Lee KE. Incidence of age-related cataract over a 15-year interval: The Beaver Dam Eye Study. Ophthalmology. 2008;115:477-482.

Klein BEK, Knudtson MD, Lee KE, Reinke JO, Danforth LG, Wealti AM, Moore E, Klein R. Supplements and age-related eye conditions: The Beaver Dam Eye Study. Ophthalmology. 2008;115(7):1203-8.

Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BEK. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXII. The twenty-five-year progression of retinopathy with persons with type 1 diabetes. Ophthalmology. 2008;115:1859-1868.

Klein BEK, Knudtson MD, Brazy P, Lee KE, Klein R. Cystatin C, other markers of kidney disease, and incidence of age-related cataract. Arch Ophthalmol. 2008;126(12):1724-30

Invited Speaker: 7th Annual Alumni Meeting of the Ophthalmology Department at Queen’s University in Belfast, Northern Ireland. October, 2008.

Ronald Klein, MD, MPH

Klein R, Moss SE, Meuer SM, Klein BEK. The 15-year cumulative incidence of retinal vein occlusion: The Beaver Dam Eye Study. Arch Ophthalmol. 2008;126(4):513-8.

Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BEK. Age-period-cohort effect on the incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2008;115(9):1460-7.

Klein R, Knudtson MD, Klein BEK, Wong TY, Cotch MF, Liu K, Cheng CY, Burke GL, Saad MF, Jacobs DR Jr, Sharrett AR. Inflammation, complement factor H, and age-related macular degeneration: the Multi-Ethnic Study of Atherosclerosis (MESA). Ophthalmology. 2008;115:1742-9.

Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BEK. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXII. The twenty-five-year progression of retinopathy with persons with type 1 diabetes. Ophthalmology. 2008;115; 1859-1868.

Invited Speaker: “The Epidemiology of AMD: A Long-Term Perspective.” 7th Annual Alumni Meeting of the Ophthalmology Department at Queen’s University in Belfast, Northern Ireland. October, 2008.

Daniel W. Knoch, MD

Medical Alumni Association’s Clinical Science Teaching Award, 2008.

Instructor/Speaker: “Postoperative CME: Prophylaxis and Management.” Midwest Regional Phacoemulsification Course. 2008.

Invited Speaker: “Review of the Secondary Glaucomas,” & “Herpetic Keratitis: Evaluation and Management.” Optometrist CME, University of Wisconsin-Madison. September 6, 2008.

Lecture: “Busted.” UW Department of Ophthalmology and Visual Sciences, Grand Rounds, Madison, Wis. April 2008.

Burton J. Kushner, MD

Izuka M, Kushner BJ. Surgical implications of the superior oblique frenulum. JAAPOS. 2008;12:27-32.

Kushner BJ. The inferior oblique muscle adherence syndrome. Arch of Ophthalmol. 2008;125:1510-1514.

Kushner BJ. The superior oblique tendon incarceration syndrome. Arch of Ophthalmol. 2008;125:170-176.

Kushner BJ. Exotropic deviations. In: Pediatric Ophthalmology and Strabismus. Ed.:Wilson E, Trivedi R, Saunders RA. Elsevier Inc.: Canada, 2008.

Leonard A. Levin, MD, PhD

Hoegger MJ, Lieven CJ, Levin LA. Differential production of superoxide by neuronal mitochondria. BMC Neurosci. 2008;9:4.

Levin LA, Danesh-Meyer H. Hypothesis: A venous etiology for nonarteritic anterior ischemic optic neuropathy. Arch Ophthalmol. 2008;126:1582-1585.

Lecture: “Lost in Translation: Bumps in the Road Between Bench and Bedside.” J.D. Allen Lectureship, University of Ottawa.

Lecture: “Breaking the Chain: Novel Compounds for Blocking Cell Death in Neuroretinal Disease.” Martin J. Steinbach Lectureship, University of Toronto.

Member: Anterior Eye Disease Study Section, National Institutes of Health.

Mark J. Lucarelli, MD

Lucarelli MJ, Ahn HB, Kulkarni AD, Kahana A. Intratarsal epidermal inclusion cyst. Ophthal Plast Reconstr Surg. 2008;24(5):357-359.

Nieto JC, Kim N, Lucarelli MJ. Dacryoadenitis and orbital myositis associated with lyme disease. Arch Ophthalmol. 2008;126(8):1165-1166.

Kim N, Lucarelli MJ. Chapter 1. “Applied Anatomy of Orbit.” In: Surgical Atlas of Orbital Diseases. Ed.: Subrahmanyam M. Jaypee Brothers Medical Publishers Ltd.: New Dehli, India. 2008.

Kahana A, Burkat CN, Lucarelli MJ, Dortzbach RK. “Diagnosis and Management of Orbital Fractures.” In: Surgical Atlas Orbital Diseases. Ed.: Subrahmanyam M. Jaypee Brothers Medical Publishers Ltd.: New Dehli, India, 2008.

Moderator: “Orbital, Lacrimal, Plastic Surgery Free Papers.” Joint Meeting of the American Academy of Ophthalmology and European Society of Ophthalmology, Atlanta. November 10, 2008.


Julie A. Mares, PhD

Moeller S, Voland R, Tinker L, Blodi B, Klein M, Gehrs K, Johnson E, Snodderly M, Wallace R, Chappell R, Parekh N, Ritenbaugh C, Mares JA. Associations between age-related nuclear cataract and lutein and zeaxanthin in the diet and rerum in the Carotenoids in Age-Related Eye Disease Study (CAREDS), an ancillary study of the Women’s Health Initiative. Arch Ophthalmol. 2008;126(3):354-364.

LaRowe TL, Mares JA, Snodderly DM, Klein ML, Wooten BR, Chappell R. Macular pigment and age-related maculopathy in the carotenoids in age-related eye disease study, an ancillary study of the Women’s Health Initiative. Ophthalmology. 2008;15(5):876-883.

Mares JA, Millen AE . Diet and supplements in the prevention and treatment of eye diseases. In: Nutrition in the Prevention and Treatment of Disease, 2nd Ed. Eds.: Coulston AM, Rock CL, Monsen E. Elsevier Inc.: San Diego. 2008.

Mares JA. Foods and supplements in the prevention and treatment of age-related macular degeneration. In: Albert and Jakobiec’s Principles and Practice of Ophthalmology, 3rd Ed. Eds.: Albert DM, Miller, JW, Azar DM, Blodi BA. Elsevier Inc.: London. 2008.

Lecture: “Lessons Learned While Studying Relationships of Diet to Eye Disease” State University of New York - Buffalo, Department of Social Sciences and Preventive Medicine. 2008.

T. Michael Nork, MD, MS

Savagian CA, Dubielzig RR, Nork TM. Comparison of the distribution of three hypoxia inducible proteins in canine glaucomatous and normal retinas. Am J Vet Res. 2008;69:265-72.

Published Abstract: Binley K, Iqball S, Nork TM, Miller P, Christian B, Kan O, Naylor S. Evaluation of EIAV based lentiviral vectors following ocular delivery in the nonhuman primate model: Development of RetinoStat®. European Society of Gene and Cell Therapy 2007.

Published Abstract: Ver Hoeve JN, Kim CBY, Nork TM, Christian BC, Miller P. Standardized full-field electroretinography in non-human primates. ARVO #5816. 2008.

Published Abstract: Nork TM, Kim CBY, Heatley GA, Kaufman PL, Lucarelli MJ, Levin LA, Ver Hoeve, JN. Long-term study of multifocal electroretinographic changes in experimental glaucoma in macaques. International Society of Clinical Electrophysiology of Vision. 2008.

Published Abstract: Neekhra A, Olsen TW, Albert DM, Nork TM. Proliferative vitreoretinopathy in siderosis bulbi. American Society of Retina Specialists. 2008.

Todd W. Perkins, MD

Instructor: “Phacoemulsification Course.” University of Wisconsin-Madison, University of Iowa, Medical College of Wisconsin. September 27, 2008.

Instructor: “Visual Fields.” American Academy of Ophthalmology, Atlanta. November 10, 2008.

Lecture: “Angle Closure Glaucoma.” UW Department of Ophthalmology and Visual Sciences, Grand Rounds, Madison, Wis. April 25, 2008.

Lecture: “Investigation of a Glaucoma Comlpication.” UW Department of Ophthalmology and Visual Sciences, Grand Rounds, Madison, Wis. September 5, 2008.

Arthur S. Polans, PhD

M.D. Matthews Retina Research Foundation Professorship. 2008.

RO1 CA103653 (Principal Investigator) Angiogenic Factors Associated With Uveal Melanoma National Cancer Institute, NIH

van Ginkel PR., Darjatmoko SR, Sareen D, Subramanian L, Bhattacharya S, Lindstrom M, Albert DM, Polans AS. Resveratrol inhibits uveal melanoma tumor growth via early mitochondrial dysfunction. Investi Ophthal Vis Sci. 2008;49:1299-1306

Lecture: “An Eye on Cancer: Resveratrol Treatment of Ocular Melanoma.” Distinguished Lecture Series, Cole Eye Center, Cleveland. 2008.

Poster: Soto BL, Hank JA, Polans AS, Sondel PM. Anti-tumor effect of resveratrol and its potential for combination with immunotherapy. American Association for Cancer Research, Annual Meeting, San Diego. April 12-16, 2008.

Stephen K. Sauer, MD

Director: Residency Core Competencies.

Lecture: “Intraocular Lens Selection.” Harvard Medical School Intensive Cataract Surgical Training Conference. 2008.

Lecture: “Teaching and Assessing Surgical Competence.” Extraordinary Ophthalmology Conference. Madison, Wis. 2008.

Lecture: “Intraocular Lens Selection.” Midwest Regional Resident Phacoemulsification Course. 2008.

Lecture: “Intraocular Lens Formulas.” Midwest Regional Resident Phacoemulsification Course. 2008.

Nader Sheibani, PhD

DiMaio TA, Wang S, Huang Q, Scheef EA, Sorenson CM, Sheibani N. Attenuation of retinal vascular development and neovascularization in PECAM-1 deficient mice. Developmental Biol. 2008;315:72-88.

Kondo S, Tang Y, Scheef EA, Sheibani N, Sorenson CM. Attenuation of retinal endothelial cell migration and capillary morphogenesis in the absence of Bcl-2. Am J Physiol Cell Physiol. 2008;294:C1521-C1530.

Huang Q, Sheibani N. High Glucose Promotes Retinal Endothelial Cell Migration through Activation of Src, PI3K/Akt1/eNOS, and ERKs. Am J Physiol Cell Physiol. 2008;295:C1647-C1657.

Invited speaker: “Thrombospondin-1 and Retinal Vascular Homeostasis.” Case Western Reserve University, Department of Ophthalmology and Visual Sciences, Cleveland. April, 2008.

Invited speaker: “Retinal Vasculature and Vascular Cells: Models to Study Vascular Effects.” 11th Congress of the International Society of Ocular Toxicology, Philadelphia. September, 2008.

Michael C. Struck, MD

Instructor: “Atropine, Occlusion and the Perils of Amblyopia Management.” Joint Meeting of the American Academy of Ophthalmology and the European Society of Ophthalmology, Atlanta. November 10, 2008.


2008 DONOR HONOR ROLL $100,000+

Research to Prevent Blindness Retina Research Foundation University of WI Medical Fdtn

$10,000-99,999

Janet D. Berger

$5,000-9,999

Barbara E. K. Klein David E. and Ann Stinchcomb

$1,000-4,999

Heebae Ahn James C. Allen Matthew D. Davis David E. Grosz Larry H. Hogan Newell D. and Helen Jasperson Albert V. and Dolores H. Kanner Irving E. Levy Ronald L. and Jean L. Lewis Mark J. and Heidi Lucarelli T. Michael Nork Mary V. H. Pratt Wanda L. Rood Isolde Schwegler Bryan S. Sires Gregory A. Stainer Artha J. Towell Catherine I. Wagner Lucille M. Warren Robert G. and Carol A. Witt Audrey A. Yahr

$500-999

Daniel M. and Eleanor Albert Frederick J. Davis Greendale Lions Club Linda K. Haskins and Kurt Waldmer Gregg A. Heatley McFarland Lioness Club Mark F. Mergen Merle L. and Barbara Perkins Charles F. Rietz Jay E. and Andrea Sobel Jaime M. Weiss Wittenberg Lions Club

<$500

Robert J. and Beverly Acker Jawdat S. and Solveig Al-Shaikhli C. Joseph Anderson Bernice E. Banks Carl E. Berg Jamie L. Birkett Roger Birkett H. Jane Blackman Rodger and Shirley A. Bobholz Robert G. and Donna M. Bradley John R. Brooks Paul M. Brusky Thomas G. and Suzan L. Buresh Oran and Ruth M. Bushman Diane S. Casey Chippewa Valley Lioness/

Lions Club Arnold L. and Kay E. Clement Ronald P. and Jane L. Danis George E. Davis C. Thomas Dow William E. Drilling Alan A. Ehrhardt Robert S. and Janelle M. Elmer

Ronald L. Engerman Ettrick Lions Club John R. Evans Eye Clinic of the Fox Valley Mary A. Farley Bobby L. Faulkner Irene Fedorovich Russell G. and Janet E. Ferris Leland E. Friedrich Julia M. Garland Betty J. Gill Julius Gomolin Greater Kenosha Lions Club Ramona S. Hagen Roger L. and Donna Hagengruber Andrew A. and Denise E. Halada Lois M. Heck Phyllis J. Hillers Eugene O. Holzmann Hudson Lions Club Inc. Richard L. and Harriet W. Huff Clare F. Hutson Gary D. and Jody J. Jensen William E. and Jane W. Johnson James W. Jukes Erwin F. Koenig Jefferey R. Lange Charles B. Larkin Columbus Lions Club Ute E. Lundy Sammy T. and Adina M. Maes Marvel A. Mapes Maurice M. and Evelyn Mehltretter Menomonie Lions Club Thomas J. and Ann E. Merfeld Fern H. Mohs Todd Murdock Susan M. Murphy Frank L. Myers

Nelson Lions Club Dept of Ophthalmology

and Visual Sciences Vincent G. Pelletier Anne W. Perina Herbert M. and Ann Poynter Charles T. Ramshaw Donny L. Reeves Wilma J. Rohweder James C. Ross Harry and Karen M. Roth Carl F. Schmidt Richard L. Schultz Mary L. Scidmore Eleanor Seekins Toby E. and Margaret T. Sherry Morton E. Smith Eric James Sobel Memorial Scholarship Fund Daniel H. Sotski Robert O. and Mary K. Spahn Sparta Lioness Club Ellen M. Stasieluk Thomas S. Stevens Seward R. and Margaret C. Stroud Rodney J. Sturm Sue C. Sweet Nasreen Syed Judy J. Thompson Robert L. and Jane Thompson L. Michael Tobin Bev Towle Trempealeau Lions Club Inc. Two Rivers Lions Club Van Dyne Lioness Club Neil F. Wienke Gregory J. and Kristine L. Winneke Gerald and Ethel Woodin Robert E. Yost

H. Edwin Young Kathy Young Stanley J. Young Richard J. Ziemann

Other contributions:

The Department of Ophthalmology and Visual Sciences receives an annual contribution from the University of Wisconsin Medical Foundation. In 2008, $372,211 was provided for research and development support as part of the Department’s participation in the clinical practice plan. Each of the department’s clinicians contributed to this partnership.

The Department of Ophthalmology and Visual Sciences gratefully acknowledges the ongoing support of Research to Prevent Blindness, the Retina Resarch Foundation, the Wisconsin Lions Foundation and the National Eye Institute.


Charles J. Anderson, MD

Donald Beresky, MD

Joseph N. Blustein, MD

Stephen M. Boorstein, MD

Christopher R. Croasdale, MD

George E. Davis, MD

Thomas Dow, MD

Richard R. Dubielzig, DVM-Affiliate

Daniel Fary, MD

Judith Fitzgerald, MD

Russell Gonnering, MD

Kara H. Harbick, MD

Jeffery W. Kalenak, MD

Bradley Lemke, MD

Neil J. Lucchese, MD

Bruce M. Massaro, MD

Peter J. McCanna, MD

Kevin B. Miller, MD

Mansoor Movaghar, MD

Christopher Murphy, DVM, PhD -Affiliate

Frank Myers, MD

Earl W. Nepple, MD

Donna Peters, PhD -Affiliate

John G. Rose, Jr., MD

Harry Roth, MD

Kurt A. Schwiesow, MD

Michael H. Scott, MD

Morton E. Smith, MD

Robert G. Smith, MD

Stephen J. Sramek, MD

Rodney J. Sturm, MD

Michael P. Vrabec, MD

John A. Vukich, MD

James P. Wise, MD

Mitchell D. Wolf, MD

VOLUNTEER & AFFILIATE FACULTY MEMbERS

2008 REVENUE SUMMARY1 PRIVATE G IFTS AND DONAT IONS $ 274,308

2 UWMF CL IN ICAL CONTR IbUT IONS FOR R&D $ 504,166

3 RESEARCH GRANTS & AWARDS $ 11,196,055

4 HOSPITAL SUPPORT $ 489,904

5 PRACT ICE PLAN $ 20,069,465

6 MEDICAL SCHOOL FACULTY SUPPORT $ 1,457,734

7 CLINICAL TRIAL & RESEARCH FEE-FOR-SERVICE AGREEMENTS $ 7,217,184


2008 SELECTED GRANTSAlbert, DanielNIH/NATIONAL CHILDHOOD CANCER FOUNDATION Children’s Oncology Group

Altaweel, Michael NIH Multicenter uvetis steroid trial

Barney, NealNIH Conjunctival mast cells in allergic eye disease

Blodi, Barbara NIH Intravitreal Corticosteroid For Macular Edema StudyNIH Standard care versus corticosteroid for retinal vein occlusion

Brandt, Curtis NIH Core Grant For Vision ResearchRRF Gene Therapy For Retinal Degenerative DiseasesNIH Promoters For Glaucoma Gene TherapyNIH Virion Sialic Acid and HSV Ocular InfectionNIH Virus Specific Factors Of HSV To Corneal Disease

Chandra, SureshNIH/EMMES CORPORATION Age-related eye disease studyNIH/UNIV OF PENNSYLVANIA Complications of age-related macular degeneration

Colley, Nansi RRF Molecular studies of retinal Degeneration in Drosophila NIH Molecular studies of retinal Degeneration in Drosophila

Cruickshanks, Karen NIH Epidemiology Of Age- Related Hearing Loss StudyNIH Familial And Birth Cohort Effects On The Aging SensesNIH/UNIV OF NORTH CAROLINA-CHAPEL HILL Episense Audiometry Reading Center

Danis, Ronald NIH/GEORGE WASHINGTON UNIVERSITY Diabetes prevention program outcome study extensionNIH Diabetic Retinopathy Clinical Research Network NIH/GEORGE WASHINGTON UNIVERSITY Epidemiology of diabetes intervention and complicationsNIH Age related eye disease study NIH Ocular Complications of Aids

Davis, Matthew NIH Ocular Complications Of AIDS

Gamm, DavidOREGON HEALTH AND SCIENCE UNIVERSITY Human stem cell-based therapies for age-related macular degenerationNIH Culture And Transplantation Of Human Retinal Sphere

Gottlieb, Justin NIH/JAEB CENTER FOR HEALTH RESEARCH Diabetic Retinopathy Clinical Research Network

Ip, Michael NIH/JAEB CENTER FOR HEALTH RESEARCH Diabetic Retinopathy Clinical Research Network

Kaufman, Paul NIH Anterior ocular segment physiology and pharmacologyAHAF Vitamin K and IOPNIH Extra-Lenticular Aspects of Accommodation and Presbyopia

Klein, Barbara RRF Associations of Retinal microvascular caliber in pregnant diabetic womenNIH Linkage studies of quantitative ocular traits Klein, Ronald NIH Epidemiology Of Diabetic RetinopathyNIH/UNIV OF TEXAS HOUSTON Genetics Of Diabetic Retinopathy StudyNIH Novel Risk Factors For Chronic Kidney DiseaseJDRF Retinal vessel diameter and diabetic nephropathy and retinopathy

Klein, Ronald; Klein, BarbaraNIH Epidemiology of Age-Related Macular Degeneration and Other Retinal DiseasesNIH/UNIV OF WASHINGTON Multi-Ethnic Study of Atherosclerosis (MESA II)

Levin, Leonard NIH Novel mitochondrial target neuroprotectants for glaucoma

Mares, Julie NIH Diet and lifestyle factors reducing risk for age-related eye disease

McLellan, Gillian NIH Structural and functional characterization of a novel Model for Glaucoma Research

Nickells, Robert AHAF Cell Based Neurotrophin Therapy For GlaucomaNIH Mapping Rgc Susceptibility Alleles In MiceNIH The Molecular Mechanisms Of Retinal Ganglion Cell Death

Polans, Arthur NIH Angiogenic Factors Associated With Uveal MelanomaRRF Inhibiting neovascular diseases of the retina: A new drug discovery

Sheibani, Nader RRF High-throughput screening of antiangiogenic compoundsNIH PECAM-1 and Retinopathy of Prematurity

Tian, Baohe NIH Will Cytoskeletal Drugs Prevent PCO?

van Ginkel, PaulAICR The role of mitochondria in resveratrol-induced cell death in human neuroblastoma

KEYFederal funding:NIH = National Institutes of Health

Foundation:AHAF = American Health Assistance FoundationAICR = American Institute for Cancer ResearchJDRF = Juvenile Diabetes Research FoundationRRF = Retina Research Foundation


This 2008 Annual Report was produced by the University of Wisconsin Department of Ophthalmology and Visual Sciences for referring physicians, doctors, donors, alumni, and friends of the department.

To have your name removed from the Annual Report mailing list or to have your address changed, please call: Amy Zimmerman at (608) 263-1480. Or send your request to: UW Department of Ophthalmology and Visual Sciences Attn: Amy Zimmerman2828 Marshall Court, Suite 106 Madison, WI 53705

UNIVERSITY OF W ISCONSIN DEPARTMENT OF OPHTHALMOLOGY AND V ISUAL SC IENCES 3310 University Ave., Suite 206 Madison, WI 53705

CHAIR Paul Kaufman, MD UW Department of Ophthalmology and Visual Sciences 3310 University Ave., Suite 206 Madison, WI 53705 608-263-6070 608-263-1466 fax

EDITOR Sarah FuellemanUW Department of Ophthalmology and Visual Sciences2870 University Ave., Suite 102Madison, WI 53705608-262-3953608-262-2212 [email protected]

ANNUAL REPORT ED ITOR IAL COMMITTEE Barbara Blodi, MD Yasmin Bradfield, MD Linda Haskins, MBA Paul Kaufman, MD Jill Cohen Kolb, MA Robert W. Nickells, PhDChristopher Temme

DESIGN & PRODUCT ION Greenleaf Media

PHOTOGRAPHY Andy Manis PhotoContributions

To contribute to the UW Department of Ophthalmology and Visual Sciences, please contact:

Nancy Francisco-WelkeSenior Director of DevelopmentUniversity of WI Foundation1848 University AvenueP.O. Box 8860Madison WI 53708-8860608-263-5960nancy.francisco-welke@uwfoundation.wisc.edu

© 2008 UW Department of Ophthalmology and Visual Sciences

mission statementto C r e a t e , i n t e g r a t e , t r a n s M i t a n d a P P l y k n o w l e d g e i n o P h t h a l M o l o g y a n d v i s u a l s C i e n C e s .

to P r o v i d e h i g h - q u a l i t y C o M P r e h e n s i v e a n d t e r t i a r y e y e C a r e f o r t h e u n i v e r s i t y h e a l t h C e n t e r , t h e Ma d i s o n C o M M u n i t y , a n d t h e s u r r o u n d i n g r e g i o n i n a n e f f i C i e n t a n d C o s t - e f f e C t i v e M a n n e r ; a n d i n s e l e C t a r e a s t o s e r v e a s a r e s o u r C e f o r t h e n a t i o n .

to f a C i l i t a t e M u l t i d i s C i P l i n a r y r e s e a r C h a n d s C i e n t i f i C d e v e l o P M e n t b y f o s t e r i n g r e s e a r C h C o l l a b o r a t i o n a n d M u t u a l l e a r n i n g , a n d t o P l a y a l e a d i n g r o l e i n r e s e a r C h , t e a C h i n g a n d C o l l a b o r a t i v e s t u d i e s r e l a t e d t o t h e v i s u a l s C i e n C e s .

to e d u C a t e M e d i C a l s t u d e n t s , o P h t h a l M o l o g i s t s -i n - t r a i n i n g ( r e s i d e n t s a n d f e l l o w s ) , P r a C t i C i n g o P h t h a l M o l o g i s t s , r e s e a r C h e r s i n v i s u a l s C i e n C e s a n d r e l a t e d d i s C i P l i n e s , n o n - o P h t h a l M o l o g y P h y s i C i a n s , n o n - o P h t h a l M o l o g y h e a l t h C a r e P r o v i d e r s a n d t h e P u b l i C .

building bridges to better vision annual report 2008 · at left, top to bottom: emily chew, md,...

Documents